Publications by authors named "M V Pryanishnikova"
Biomark Insights
December 2015
Article Synopsis
- The introduction of tyrosine kinase inhibitors (TKIs), specifically imatinib, has improved survival rates for chronic myeloid leukemia (CML) patients, but some develop resistance due to mutations in the BCR-ABL gene.
- Patients resistant to imatinib can often benefit from second-generation TKIs like nilotinib and dasatinib, with treatment decisions based on specific mutations.
- In a reported case, a CML patient with primary resistance to imatinib and an F317L mutation was successfully treated with dasatinib and underwent allogeneic stem cell transplantation, using dasatinib post-transplant to prevent relapse.
